This AsseraChrom HPIA test kit, which was recently FDA-cleared, is an ELISA-based assay for the detection of anti-heparin-platelet factor 4 (PF4) antibodies associated with immune-mediated heparin-induced thrombocytopenia (HIT Type II).
It is estimated that approximately 2 to 4 percent of patients exposed to heparin will mount an immune reaction with the development of antibodies primarily directed towards a heparin-PF4 complex. This disorder is characterized by a rapid drop in platelet count that is normalized by discontinuation of the heparin.
Of these patients, approximately 25 percent will go on to develop thrombosis with potential life-threatening consequences. Due to the potential severity of HIT Type II and the associated thrombotic complications, the laboratory identification of heparin-PF4 antibodies is desirable.
Diagnostica Stago
www.stago-us.com
Keyword: anti-heparin-platelet factor, ELISa
